Table 5.
Comparison of MACE* at 5 Years According to Stress Tests Results and Presence of CMD
| Patient number | Cumulative incidence | Univariable | Multivariable † | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | Adjusted HR (95% CI) | P value | |||
| Group 1: INOCA(−)/CMD(−) | 116 (40.4%) | 7 (7.4%) | Reference | Reference | ||
| Group 2: INOCA(−)/CMD(+) | 90 (31.4%) | 15 (21.3%) | 3.18 (1.30–7.82) | 0.012 | 2.88 (1.51–7.19) | 0.024 |
| Group 3: INOCA(+)/CMD(−) | 41 (14.3%) | 3 (7.7%) | 1.56 (0.40–6.04) | 0.523 | 1.32 (0.33–5.27) | 0.697 |
| Group 4: INOCA(+)/CMD(+) | 40 (13.9%) | 8 (34.4%) | 4.78 (1.71–13.40) | 0.003 | 4.00 (1.41–11.35) | 0.009 |
Data expressed as number of events (%). The cumulative incidence of clinical outcomes is presented as Kaplan–Meier estimates during median follow‐up of 1194.0 days (Q1–Q3, 730.0–1826.0 days). CMD indicates coronary microvascular disease; HR, hazard ratio; INOCA, ischemia with no obstructive coronary arteries; and MACE, major adverse cardiac event.
Defined as the composite of all‐cause death, acute myocardial infarction not clearly attributable to a nontarget vessel, and any revascularization by means of coronary bypass grafting or percutaneous coronary intervention.
Adjusted for age, sex, diabetes, hyperlipidemia, and previous percutaneous coronary intervention.